Tag: NASDAQ:ZIOP

FB Nasdaq FB Facebook
Finance

Biotech losers: ZIOPHARM Oncology (NASDAQ:ZIOP), Sangamo Biosciences (NASDAQ:SGMO), Lexicon Pharmaceuticals (NASDAQ:LXRX), XOMA Corp (NASDAQ:XOMA)

On Apr 3, Zacks Investment Research upgraded ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) to Zacks Rank #1 (Strong Buy). ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)’s loss estimates have declining on the back of better-than-expected fourth quarter 2013 results. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) stock performance was -6.06% in last session and finished the day at $4.34. Traded volume was 1.86million shares in the last session and the average volume of … Continue reading Biotech losers: ZIOPHARM Oncology (NASDAQ:ZIOP), Sangamo Biosciences (NASDAQ:SGMO), Lexicon Pharmaceuticals (NASDAQ:LXRX), XOMA Corp (NASDAQ:XOMA)

Colin Pettis
Finance

Volatile Stocks at Biotech: ZIOPHARM Oncology (NASDAQ:ZIOP), Idenix Pharmaceuticals (NASDAQ:IDIX), Synthetic Biologics (NYSEMKT:SYN), Ariad Pharmaceuticals (NASDAQ:ARIA)

Looking back to 160 days ago, ZIOPHARM Oncology Inc (NASDAQ:ZIOP) priced a 14,300,000 share secondary stock offering at $3.50 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time and based on early trading on Wednesday. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) stock performance was -3.75% in last session and finished the … Continue reading Volatile Stocks at Biotech: ZIOPHARM Oncology (NASDAQ:ZIOP), Idenix Pharmaceuticals (NASDAQ:IDIX), Synthetic Biologics (NYSEMKT:SYN), Ariad Pharmaceuticals (NASDAQ:ARIA)

Kristen Barton
Finance

Biotech Gainers: Fate Therapeutics Inc (NASDAQ:FATE), ZIOPHARM Oncology (NASDAQ:ZIOP), Uniqure NV (NASDAQ:QURE), Sorrento Therapeutics (NASDAQ:SRNE)

Fate Therapeutics Inc (NASDAQ:FATE) recently issued a statement that it has enrolled it first patient for the second phase of this study. The primary aim of the PUMA study is to assess the efficacy and safety of PROHEMA in a randomized, controlled environment for patients that are under treatment for hematopoietic stem cell or HSC transplantation for hematologic malignancies. Fate Therapeutics Inc (NASDAQ:FATE) stock performance … Continue reading Biotech Gainers: Fate Therapeutics Inc (NASDAQ:FATE), ZIOPHARM Oncology (NASDAQ:ZIOP), Uniqure NV (NASDAQ:QURE), Sorrento Therapeutics (NASDAQ:SRNE)

Colin Pettis
Finance

Top Morning News: ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), Barrick Gold Corporation (NYSE:ABX), FireEye, Inc. (NASDAQ:FEYE), Cass Information Systems (NASDAQ:CASS), Power Solutions International (NASDAQ:PSIX)

Shares of ZIOPHARM Oncology (NASDAQ:ZIOP) saw a significant decrease in short interest in December. As of December 15th, there was short interest totalling 17,601,779 shares, a decrease of 5.8% from the November 28th total of 18,695,183 shares, AnalystRatingsNetwork.com reports. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) belongs to Healthcare sector. Its weekly performance is 8.10%. On last trading day company shares ended up $5.07. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) … Continue reading Top Morning News: ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), Barrick Gold Corporation (NYSE:ABX), FireEye, Inc. (NASDAQ:FEYE), Cass Information Systems (NASDAQ:CASS), Power Solutions International (NASDAQ:PSIX)

Chris Lewis
Finance

Volatile Stocks: Prosensa Holding (NASDAQ:RNA), 22nd Century Group Inc (NYSEMKT:XXII), Alnylam Pharmaceuticals (NASDAQ:ALNY), AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)

Prosensa Holding NV (NASDAQ:RNA) was upgraded by stock analysts at KBC Securities from a “hold” rating to an “accumulate” rating in a report issued on Wednesday. The firm currently has a $11.00 price objective on the stock, up from their previous price objective of $7.00. KBC Securities’ target price would indicate a potential upside of 1.57% from the company’s current price. Prosensa Holding NV (NASDAQ:RNA) … Continue reading Volatile Stocks: Prosensa Holding (NASDAQ:RNA), 22nd Century Group Inc (NYSEMKT:XXII), Alnylam Pharmaceuticals (NASDAQ:ALNY), AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)

Colin Pettis
Finance

NASDAQ Gainers: Rediff.com India Limited (ADR) (NASDAQ:REDF), Keurig Green Mountain Inc (NASDAQ:GMCR), Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)

Rediff.com India Limited (ADR) (NASDAQ:REDF) released its 4Q and full-year financial performance that showed somehow wanting results especially in the U.S. However, investors appeared to pay little attention to the U.S. business problems but instead looked forward to better results in the near future, just as the management promised. Rediff.com India Limited (ADR) (NASDAQ:REDF) stock performance was 23.01% in last session and finished the day … Continue reading NASDAQ Gainers: Rediff.com India Limited (ADR) (NASDAQ:REDF), Keurig Green Mountain Inc (NASDAQ:GMCR), Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)

Jason Knox